Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.

about

PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.

P2860

Q35948581-1C6D2EF1-8FCC-4D53-AB5A-186870321B62 Q36765341-344294E1-90F6-472F-B1B1-7FC98528409E Q48008350-E47E2380-AC95-46C7-ACA0-84F3DD3A082A

P2860

Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.

Item

http://www.wikidata.org/entity/Q38238598

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Anticipating mechanisms of res ...... the era of precision medicine.

@en

type

Item

label

Anticipating mechanisms of res ...... the era of precision medicine.

@en

prefLabel

Anticipating mechanisms of res ...... the era of precision medicine.

@en

P1476

Anticipating mechanisms of res ...... the era of precision medicine

@en

P2093

Cedric Leroy

http://www.w3.org/2001/XMLSchema#string

Mohamed Bentires-Alj

http://www.w3.org/2001/XMLSchema#string

P2860

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

A coding-independent function of gene and pseudogene mRNAs regulates tumour biology

What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway

Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway

Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor

Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers

Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors

PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma

P304

733-741

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1042/BST20140034

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Romain J Amante

P577

2014-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25109950

http://www.w3.org/2001/XMLSchema#string

Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.

about

P2860

P2860

Anticipating mechanisms of resistance to PI3K inhibition in breast cancer: a challenge in the era of precision medicine.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698